Therapeutic potency of oncolytic virotherapy in breast cancer targeting, current status and perspective

J Cell Biochem. 2019 Mar;120(3):2801-2809. doi: 10.1002/jcb.27725. Epub 2018 Sep 27.

Abstract

Breast cancer is the most common cause of cancer death in women and presents a serious therapeutic challenge worldwide. Traditional treatments are less successful at targeting cancer tumors, leading to recurrent treatment-resistant secondary malignancies. Oncolytic virotherapy (OV) is a novel anticancer strategy with therapeutic implications at targeting cancer cells by using mechanisms that differ from conventional therapies. Administration of OVs either alone or in combination with standard therapies provide new insights regarding the effectiveness and improvement of treatment responses for breast cancer patients. This review summarizes cellular, animal and clinical studies investigating therapeutic potency of oncolytic virotherapy in breast cancer treatment for a better understanding and hence a better management of this disease.

Keywords: breast tumor; cancer stem cell; oncolytic virotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Female
  • Humans
  • Neoplastic Stem Cells / pathology
  • Oncolytic Virotherapy / trends*
  • Oncolytic Viruses / genetics
  • Oncolytic Viruses / physiology
  • Receptors, Virus / metabolism
  • Transgenes

Substances

  • Receptors, Virus